ID

42960

Descrizione

see http://clinicaltrials.gov/ct2/show/study/NCT00048295 ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation. People with Crohn’s disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the “instruction” molecule that is required for the production of ICAM-1 protein. This trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at </= 30 mg per day.

collegamento

http://clinicaltrials.gov/ct2/show/study/NCT00048295

Keywords

versioni (4)

1. 14/11/11 14/11/11 -
2. 14/11/11 14/11/11 -
3. 22/03/14 22/03/14 - Martin Dugas
4. 17/09/21 17/09/21 -

Caricato su

17 settembre 2021

DOI

Per favore, per richiedere un accesso.

Licenza